• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经认知评估非典型性畸胎样横纹肌样肿瘤(ATRT)的长期幸存者:加拿大登记处的经验。

Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): The Canadian registry experience.

机构信息

Division of Hematology Oncology Bone Marrow Transplantation, Alberta Children's Hospital, Calgary, Alberta, Canada.

Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.

出版信息

Pediatr Blood Cancer. 2015 Jul;62(7):1265-9. doi: 10.1002/pbc.25441. Epub 2015 Mar 18.

DOI:10.1002/pbc.25441
PMID:25787232
Abstract

BACKGROUND

Because atypical teratoid rhabdoid tumor(ATRT) is a rare disease of infancy carrying a grim prognosis, focus on long-term outcome, especially neurocognitive remained very limited. With new era of multimodality therapy, an increasing proportion of patients are now long-term survivors.

PROCEDURE

Retrospective review of neuropsychological (NP) status of survivors from the Canadian ATRT registry.

RESULTS

Among 77 patients diagnosed between 1995-2012, 16(22%) were survivors. Formal NP assessments were available in eight patients. Partial information on academic achievement was available on three additional patients. There were four girls and seven boys diagnosed at a median age of 27.5 months. Seven patients underwent complete resection and three had metastatic disease. All but one received sequential high dose chemotherapy. Five patients received intrathecal chemotherapy. Three patients underwent radiation. Median age at time of formal NP assessment was 7.6 years (3.9-9.8). Full Scale Intellectual Quotient (FSIQ) ranged from less than 50-119 (mean 78). Simple expressive and receptive language appeared relatively preserved. Three recently diagnosed patients (median time assessment from diagnosis 2.6 years (1.6-4.7)) had average to high average FSIQ, academic and visual spatial skills, visual, and verbal memory. Five other patients diagnosed earlier and tested at a median time of 4.9 years (3.3-8.3) post-diagnosis had a FSIQ ranging from <50 to 71. Approximately 50% of their scores were in the impaired range.

CONCLUSION

Overall this cohort appears significantly impaired at school age despite the absence of systematic radiotherapy. Larger series focusing on neurocognitive outcome are needed in the current context where treatment strategies include adjuvant radiation.

摘要

背景

由于婴儿罕见的间叶性横纹肌样肿瘤(ATRT)预后较差,因此重点关注长期预后,特别是神经认知方面的预后,这方面的研究仍然非常有限。随着多模式治疗新时代的到来,越来越多的患者现在成为长期幸存者。

方法

回顾性分析加拿大 ATRT 登记处幸存者的神经心理学(NP)状况。

结果

在 1995 年至 2012 年间诊断的 77 名患者中,有 16 名(22%)为幸存者。对 8 名患者进行了正式的 NP 评估。另外 3 名患者提供了部分学业成绩信息。4 名女孩和 7 名男孩被诊断为中位年龄 27.5 个月。7 名患者接受了完全切除术,3 名患者发生了转移性疾病。除 1 名患者外,所有患者均接受了序贯高剂量化疗。5 名患者接受了鞘内化疗。3 名患者接受了放疗。正式 NP 评估的中位年龄为 7.6 岁(3.9-9.8)。全量表智商(FSIQ)范围从低于 50-119(平均 78)。简单的表达和接受语言似乎相对保留。最近诊断的 3 名患者(从诊断到评估的中位时间为 2.6 年(1.6-4.7))具有平均至高平均 FSIQ、学业和视觉空间技能、视觉和语言记忆。另外 5 名患者更早被诊断并在诊断后 4.9 年(3.3-8.3)的中位时间进行测试,FSIQ 范围从低于 50 到 71。他们大约 50%的分数处于受损范围内。

结论

尽管没有系统的放疗,但在这个时代,治疗策略包括辅助放疗,本队列在学龄期总体上明显受损。在当前的治疗背景下,需要更大规模的系列研究来关注神经认知结果。

相似文献

1
Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): The Canadian registry experience.神经认知评估非典型性畸胎样横纹肌样肿瘤(ATRT)的长期幸存者:加拿大登记处的经验。
Pediatr Blood Cancer. 2015 Jul;62(7):1265-9. doi: 10.1002/pbc.25441. Epub 2015 Mar 18.
2
Survivors of infant atypical teratoid/rhabdoid tumors present with severely impaired cognitive functions especially for fluid intelligence and visual processing: data from the German brain tumor studies.婴儿非典型畸胎样/横纹肌样瘤幸存者存在严重的认知功能受损,尤其是在流体智力和视觉处理方面:来自德国脑肿瘤研究的数据。
Pediatr Blood Cancer. 2024 May;71(5):e30910. doi: 10.1002/pbc.30910. Epub 2024 Feb 11.
3
Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience.中枢神经系统非典型畸胎样横纹肌样肿瘤:加拿大儿科脑肿瘤联盟的经验。
Eur J Cancer. 2012 Feb;48(3):353-9. doi: 10.1016/j.ejca.2011.09.005. Epub 2011 Oct 22.
4
Spinal cord atypical teratoid/rhabdoid tumors in children: Clinical, genetic, and outcome characteristics in a representative European cohort.儿童脊髓非典型畸胎样/横纹肌样肿瘤:在一个有代表性的欧洲队列中的临床、遗传和结局特征。
Pediatr Blood Cancer. 2020 Jan;67(1):e28022. doi: 10.1002/pbc.28022. Epub 2019 Oct 1.
5
Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.非典型畸胎样/横纹肌样瘤(ATRT):3岁及以上儿童接受放射治疗和基于高剂量烷化剂的化疗后生存率提高。
J Clin Oncol. 2005 Mar 1;23(7):1491-9. doi: 10.1200/JCO.2005.05.187.
6
Atypical teratoid/rhabdoid tumors of the central nervous system: management and outcomes.中枢神经系统非典型畸胎样/横纹肌样肿瘤:治疗与预后
Neurosurg Focus. 2005 Jun 15;18(6A):E8.
7
Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis.在监测、流行病学和最终结果分析中,接受放疗的非典型畸胎样横纹肌样瘤患者的生存结果。
Cancer. 2012 Sep 1;118(17):4212-9. doi: 10.1002/cncr.27373. Epub 2011 Dec 27.
8
Clinical and pathological features of paediatric malignant rhabdoid tumours.儿童恶性横纹肌样瘤的临床和病理特征
Pediatr Blood Cancer. 2010 Jan;54(1):29-34. doi: 10.1002/pbc.22231.
9
Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature.1岁以内儿童的非典型畸胎样横纹肌样瘤:加拿大非典型畸胎样横纹肌样瘤登记处的经验及文献综述
J Neurooncol. 2017 Mar;132(1):155-162. doi: 10.1007/s11060-016-2353-0. Epub 2017 Jan 19.
10
A prospective neurocognitive evaluation of children treated with additional chemotherapy and craniospinal irradiation following isolated central nervous system relapse in acute lymphoblastic leukemia.对急性淋巴细胞白血病孤立中枢神经系统复发后接受额外化疗和颅脊髓照射治疗的儿童进行的前瞻性神经认知评估。
Int J Radiat Oncol Biol Phys. 1995 Feb 1;31(3):561-6. doi: 10.1016/0360-3016(94)00432-K.

引用本文的文献

1
High-throughput screening of FDA-approved drugs identifies colchicine as a potential therapeutic agent for atypical teratoid/rhabdoid tumors (AT/RTs).对美国食品药品监督管理局(FDA)批准药物的高通量筛选确定秋水仙碱为非典型畸胎样/横纹肌样瘤(AT/RTs)的一种潜在治疗药物。
RSC Adv. 2025 Apr 17;15(16):12331-12341. doi: 10.1039/d5ra01341k. eCollection 2025 Apr 16.
2
What Have We Learnt from the Recent Multimodal Managements of Young Patients with ATRT?我们从近期对年轻非典型畸胎瘤样/横纹肌样瘤(ATRT)患者的多模式治疗中学到了什么?
Cancers (Basel). 2025 Mar 26;17(7):1116. doi: 10.3390/cancers17071116.
3
SIRT2 Regulates the SMARCB1 Loss-Driven Differentiation Block in ATRT.
SIRT2调节ATRT中由SMARCB1缺失驱动的分化阻滞。
Mol Cancer Res. 2025 Jun 3;23(6):515-529. doi: 10.1158/1541-7786.MCR-24-0926.
4
Rhabdoid tumor predisposition syndrome: A historical review of treatments and outcomes for associated pediatric malignancies.横纹肌瘤易感综合征:相关儿童恶性肿瘤治疗与预后的历史回顾
Pediatr Blood Cancer. 2024 Jun;71(6):e30979. doi: 10.1002/pbc.30979. Epub 2024 Mar 30.
5
Feeder-free differentiation of human iPSCs into natural killer cells with cytotoxic potential against malignant brain rhabdoid tumor cells.将人诱导多能干细胞无饲养层分化为对恶性脑横纹肌样瘤细胞具有细胞毒性潜力的自然杀伤细胞。
Bioact Mater. 2024 Mar 8;36:301-316. doi: 10.1016/j.bioactmat.2024.02.031. eCollection 2024 Jun.
6
Targeting cholesterol biosynthesis for AT/RT: comprehensive expression analysis and validation in newly established AT/RT cell line.针对 AT/RT 的胆固醇生物合成靶向治疗:在新建立的 AT/RT 细胞系中的全面表达分析和验证。
Hum Cell. 2024 Mar;37(2):523-530. doi: 10.1007/s13577-023-01022-1. Epub 2024 Feb 8.
7
Current Molecular and Clinical Landscape of ATRT - The Link to Future Therapies.非横纹肌样瘤的当前分子与临床概况——与未来治疗的关联
Cancer Manag Res. 2023 Dec 7;15:1369-1393. doi: 10.2147/CMAR.S379451. eCollection 2023.
8
Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT).非典型畸胎样横纹肌样瘤(ATRT)免疫治疗的当前进展。
Neurooncol Pract. 2023 Jan 28;10(4):322-334. doi: 10.1093/nop/npad005. eCollection 2023 Aug.
9
Pediatric Posterior Fossa ATRT: A Case Report, New Treatment Strategies and Perspectives.小儿后颅窝非典型畸胎样/横纹肌样瘤:一例报告、新治疗策略及展望
Brain Sci. 2023 Apr 24;13(5):712. doi: 10.3390/brainsci13050712.
10
Epigenetic Regulation in Primary CNS Tumors: An Opportunity to Bridge Old and New WHO Classifications.原发性中枢神经系统肿瘤中的表观遗传调控:连接新旧世界卫生组织分类的契机。
Cancers (Basel). 2023 Apr 27;15(9):2511. doi: 10.3390/cancers15092511.